(DOAC interactions) Cancer-treatment specific inducers ...

(DOAC interactions) Cancer-treatment specific inducers (↑) and inhibitors (↓)

of cytochrome p450 CYP3A4 and P-glycoprotein.

DOACs are substrates to CYP3A4 and P-glycoprotein enzymes. Inducers of these enzymes may potentially increase

metabolization of DOACs thereby leading to lower plasma concentrations, and inhibitors

may decrease metabolization leading to higher plasma concentrations. Edoxaban,

rivaroxaban, and apixaban are reported to have major interactions with the P-glycoprotein

pathway. Rivaroxaban and apixaban are reported to have major interactions with the

CYP3A4 pathway whereas edoxaban has been reported to have minor interactions.

Dabigatran has moderate interactions with the P-glycoprotein pathway. The extent to which

plasma concentrations of DOACs are influenced by inducers or inhibitors of CYP3A4 and

P-glycoprotein is unknown.

Source: http://www.bloodjournal.org/content/133/4/291

#DOAC #CYP3A4 #Pglycoprotein #inducers #inhibitors #Chemotherapy #Oncology #Hematology #Interactions #Table #Pharmacology
Contributed by

Dr. Gerald Diaz
Board Certified Internal Medicine Hospitalist, GrepMed Editor in Chief 🇵🇭 🇺🇸 - Sign up for an account to like, bookmark and upload images to contribute to our community platform. Follow us on IG:  https://www.instagram.com/grepmed/ | Twitter: https://twitter.com/grepmeded/
Medical jobs
view all


Related content